On heels of $100M raise, Annexon joins burgeoning IPO queue

Asian biopharma IPOs headline week that had three U.S. companies enter NASDAQ IPO queue

Two days after raising $100 million in a series D round heavy with crossover investors, Annexon has filed to go public on NASDAQ.

The filing adds to a burgeoning IPO queue and caps another busy week for newly public or soon-to-be public companies. Headlining the week were a pair of Asian biopharmas: SK Biopharmaceuticals Co. Ltd. (KRX:326030), which raised nearly $800 million on the Korea Exchange, and Gan & Lee Pharmaceuticals (Shanghai:603087). Gan &

Read the full 738 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE